Analysts Adjust Price Targets for Carlsmed Following Q3 Results

Following Carlsmed's third-quarter 2026 financial results, analysts have updated their outlooks for the company. Needham raised its price target on Carlsmed shares to $22 from $17, maintaining a Buy rating. Truist Securities also adjusted its price target on the stock to $23 from $20, while keeping a Buy rating. These actions follow the company's report of 65% revenue growth and an upward revision to its full-year 2026 revenue guidance.